葛瑞夫茲氏病的全球市場:2022-2028年

全球葛瑞夫茲氏病的市場規模在預測期間內預計將以4.2％的年複合成長率成長。

甲狀腺疾病等自身免疫性疾病的日益流行正在推動市場。有效治療格雷夫斯病的技術進步、有利的報銷政策的存在、開發新療法的資金等估計也將推動市場的增長。

本報告提供全球葛瑞夫茲氏病的市場調查，彙整市場概要，市場成長的各種影響因素分析，市場規模的轉變·預測，各種區分·地區/各主要國家的明細，競爭環境，主要企業簡介等資訊。

目錄

第1章 報告概要

第2章 市場概要·洞察

第3章 競爭情形

• 主要企業分析
• 主要策略分析

第4章 市場決策要素

• 推動要素
• 阻礙因素
• 機會

第5章 市場分析:各種類

• 全球葛瑞夫茲氏病市場:診斷
  • 超音波
  • 影像檢查
  • 放射性碘攝取率 (RAIU)
  • 血液樣品
• 全球葛瑞夫茲氏病市場:不同治療
  • 抗甲狀腺藥
  • 放射性碘療法
  • 手術

第6章 地區分析

• 北美
• 歐洲
• 亞太地區
• 其他地區

第7章 企業簡介

• AbbVie Inc.
• Abbott Laboratories
• Acella Pharmaceuticals, LLC
• Allergan PLC
• ApitopeInternational N.V.
• AstraZeneca PLC
• Bayer AG
• Biomerieux S.A.
• East West Pharma
• EpiVax, Inc.
• F.Hoffman-La-Roche AG
• GlaxoSmithKline plc.
• Lupin, Ltd.
• Macleods Pharmaceuticals Ltd.
• Merck KGaA
• Mylan N.V.
• Novartis International AG
• Pfizer Inc.
• RLC Labs
• Sanofi S.A.
• Takeda Pharmaceutical Co.Ltd.
• Torrent Pharmaceuticals, Ltd.

Global Graves' Disease Market Research by Diagnosis (Ultrasound, Imaging tests, Radioactive iodine uptake, and Blood sample), by Treatment (Antithyroid medication, Radioactive iodine therapy, and Surgery), And Forecast 2021-2027

The global graves' disease market is growing at a CAGR of 4.2% during the forecast period. The growing prevalence of auto-immune disorders such as thyroid disorder has created the demand for its treatment which in turn is driving the graves' disease market. Advancement in treatment technology for effective treatment of graves' disease is one of the prime factors to drive the market growth. Further, the existence of favorable reimbursement policies, funding in the development of novel therapies among others are also estimated to drive the growth of the market. Reimbursement policies and practices reflect the considerable impact on the expansion of healthcare facilities, diagnosis services, and R&D activities. Reimbursement policies control the work of the research and development companies without any budget concerns and with better decisions and strategies. R&D of any drug and supporting policies go hand in hand. Better reimbursement policies draw significant spending on healthcare, particularly in research and development. Reimbursements offered by many governments and private insurance companies for Grave's disease diagnosis and treatment are furthermore augmenting the growth of Grave's disease market.

The higher inclination of the population towards a sedentary lifestyle is a significant cause of diseases related to the thyroid including hyperthyroidism, hypothyroidism, autoimmune diseases, goiter, and others. The growing trend of smoking, drinking alcohol, and unhealthy eating activity in emerging and developing countries due to sedentary lifestyles has to lead to severe auto-immune disorders. The development of new technologies that have allowed ultrasound to become more widely adopted for soft tissue diagnosis across the globe is anticipated to offer lucrative opportunities for market growth during the forecast period. However, the high cost of treatment of Graves disorders and the unavailability of skilled medical professionals in developing and under-developed economies are certain factors that are hindering the growth of the market.

Segmental Outlook

The market is segmented based on diagnosis and treatment. Based on the diagnosis, the market is segmented into ultrasound, imaging tests, radioactive iodine uptake, and blood sample. Ultrasound diagnosis method in Grave's diseases market is growing at the highest CAGR during the forecast period attributed to the increasing advancement in ultrasound technology and significant contribution of major players such as Phillips, Toshiba, GE Healthcare, and Abbott providing ultrasound across the globe. Based on the treatment segment, the market is segmented into anti-thyroid medication, radioactive iodine therapy, and surgery.

Global Graves' Disease Market Share Treatment, 2020 (%)

Global Graves' Disease Market Share Treatment

Anti-Thyroid Medication Held Major Market Share in 2020

Based on the treatment segment, the anti-thyroid medication segment held a major market share in 2020. This is due to the fact that it is the most common treatment for Grave's disease. Antithyroid medications include Propylthiouracil (PTU) and Methimazole (Tapazole). These drugs prevent the thyroid to produce excess amounts of the hormone. One of the advantages provided by the PTU is that it possesses a lower risk of birth defects; hence, it is the treatment that is firstly preferred by pregnant women. PTU drugs are used for those who cannot tolerate MMI, radioactive iodine therapy, or surgery. With the anti-thyroid medications, the coupling reaction of monoiodotyrosine and diiodotyrosine for producing T3 and T4 is blocked, and therefore, the synthesis of thyroid hormone is prevented.

Regional Outlooks

Global graves' disease market analyzed based on the geographical regions that are contributing significantly towards the growth of the market. Based on the geography, the market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America held a major market share in the graves' disease market in North America. The high prevalence of thyroid disorders, significant awareness about thyroid treatment and diagnosis, and availability of various treatment options due to advanced healthcare infrastructure are some of the key factors that are contributing to the high share of this regional market. Moreover, in Europe, the changing lifestyle and the growing prevalence of type-1 diabetes among others are some factors affecting the growth in the region. Asia-Pacific is estimated to be the remarkable growth during the forecast period 2021-2027.

Global Graves' Disease Market, by Region 2021-2027

Global Graves' Disease Market, by Region

Asia-Pacific Will Have Considerable Growth in the Global Graves' Disease Market

Asia-Pacific region is expected to witness significant growth in the graves' disease market. The rising prevalence of the autoimmune disorder, increasing awareness among people with regards to graves' disease treatment are the key factors to drive the growth of the regional market. Further, development in treatment technologies, improving healthcare infrastructure, and increasing public health programs are some other factors to drive the growth of the market in the Asia-Pacific region. Moreover, the increasing prevalence of diabetes in the region, especially in China, is one of the other major factors augmenting the market growth in the region. Asia-Pacific comprises of large low- and middle-income population base, owing to which, the people generally adopt cost-effective treatment solutions such as anti-thyroid medications. Moreover, the rising healthcare spending in the emerging economies of the region is expected to provide the medical solution to the poor healthcare infrastructure of some underdeveloped countries in the region such as Indonesia.

Market Players Outlook

Key players of the graves' disease market include Rodos Biotarget GmbH, Sanofi Genzyme, Macleods Pharmaceuticals Ltd., Apitope International N.V., RLC Labs Inc. Takeda Pharmaceutical Co., Ltd., and Omeros Corp. To remain competitive in the market, these players adopt different marketing strategies such as product launches, mergers & acquisitions, and partnerships among others.

Recent Development

In July 2018, the German Federal Institute for Drugs and Medical Devices has given acceptance in 21 countries of the EU for a new formulation by Merck KGaA named Euthyrox (levothyroxine). Euthyrox is expected to have better control over individual levothyroxine dosage as the active ingredient is in the new formulation of Euthyrox enables patients.

In April 2018, Apitope Technology (Bristol) Ltd. announced the positive results of the phase I clinical trial of its product candidate ATX-GD-59 that is used for the treatment of Grave's disease. This would allow the company to expand its market in Grave's disease treatment. This strategy would help gain a significant market share in the future by having a 'first-mover advantage' unless a rival company launches a similar product.

The Report Covers

Market value data analysis of 2020 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global graves disease market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where in the market.

Table of Contents

1. Report Summary

• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. By Geography

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Findings
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion

3. Competitive Landscape

• 3.1. Key Company Analysis
  • 3.1.1. Overview
  • 3.1.2. Financial Analysis
  • 3.1.3. SWOT Analysis
  • 3.1.4. Recent Developments
• 3.2. Key Strategy Analysis

4. Market Determinants

• 4.1. Motivators
• 4.2. Restraints
• 4.3. Opportunities

5. Market Segmentation

• 5.1. Global Graves' Disease market by Diagnosis
  • 5.1.1. Ultrasound
  • 5.1.2. Imaging Tests
  • 5.1.3. Radioactive Iodine Uptake
  • 5.1.4. Blood Sample
• 5.2. Global Graves' Disease Market by Treatment
  • 5.2.1. Anti- Thyroid Medication
  • 5.2.2. Radioactive Iodine Therapy
  • 5.2.3. Surgery

6. Regional Analysis

• 6.1. North America
  • 6.1.1. United States
  • 6.1.2. Canada
• 6.2. Europe
  • 6.2.1. UK
  • 6.2.2. Germany
  • 6.2.3. Italy
  • 6.2.4. Spain
  • 6.2.5. France
  • 6.2.6. Rest of Europe
• 6.3. Asia-Pacific
  • 6.3.1. China
  • 6.3.2. India
  • 6.3.3. Japan
  • 6.3.4. South Korea
  • 6.3.5. Rest of Asia-Pacific
• 6.4. Rest of the World

7. Company Profiles

• 7.1. AbbVie Inc.
• 7.2. Abbott Laboratories
• 7.3. Acella Pharmaceuticals, LLC
• 7.4. Allergan PLC
• 7.5. ApitopeInternational N.V.
• 7.6. AstraZeneca PLC
• 7.7. Bayer AG
• 7.8. Biomerieux S.A.
• 7.9. East West Pharma
• 7.10. EpiVax, Inc.
• 7.11. F.Hoffman-La-Roche AG
• 7.12. GlaxoSmithKline plc.
• 7.13. Lupin, Ltd.
• 7.14. Macleods Pharmaceuticals Ltd.
• 7.15. Merck KGaA
• 7.16. Mylan N.V.
• 7.17. Novartis International AG
• 7.18. Pfizer Inc.
• 7.19. RLC Labs
• 7.20. Sanofi S.A.
• 7.21. Takeda Pharmaceutical Co.Ltd.
• 7.22. Torrent Pharmaceuticals, Ltd.

LIST OF TABLES

• 1. GLOBAL GRAVES' DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
• 2. GLOBAL ULTRASOUND MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 3. GLOBAL IMAGING TESTS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 4. GLOBAL RADIOACTIVE IODINE UPTAKE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 5. GLOBAL BLOOD SAMPLE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 6. GLOBAL GRAVES' DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
• 7. GLOBAL ANTI- THYROID MEDICATION MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 8. GLOBAL RADIOACTIVE IODINE THERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
• 9. GLOBAL SURGERY MARKET RESEARCH AND ANALYSISBY REGION, 2020-2027 ($ MILLION)
• 10. NORTH AMERICAN GRAVES' DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
• 11. NORTH AMERICAN GRAVES' DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
• 12. NORTH AMERICAN GRAVES' DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
• 13. EUROPEAN GRAVES' DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
• 14. EUROPEAN GRAVES' DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
• 15. EUROPEAN GRAVES' DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
• 16. ASIA-PACIFIC GRAVES' DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
• 17. ASIA-PACIFIC GRAVES' DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
• 18. ASIA-PACIFIC GRAVES' DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
• 19. REST OF THE WORLD GRAVES' DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
• 20. REST OF THE WORLD GRAVES' DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)

LIST OF FIGURES

1. GLOBAL GRAVES' DISEASE MARKET SHARE BY DIAGNOSIS, 2020 VS 2027 (IN %)

2. GLOBAL GRAVES' DISEASE MARKET SHARE BY TREATMENT, 2020 VS 2027 (IN %)

3. GLOBAL ULTRASOUND MARKET SIZE, 2020-2027 ($MILLION)

4. GLOBAL IMAGING TESTS MARKET SIZE, 2020-2027 ($MILLION)

5. GLOBAL RADIOACTIVE IODINE UPTAKE MARKET SIZE, 2020-2027 ($MILLION)

6. GLOBAL BLOOD SAMPLE MARKET SIZE, 2020-2027 ($MILLION)

7. GLOBAL ANTI- THYROID MEDICATION MARKET SIZE, 2020-2027 ($MILLION)

8. GLOBAL RADIOACTIVE IODINE THERAPY MARKET SIZE, 2020-2027 ($MILLION)

9. GLOBAL SURGERY MARKET SIZE, 2020-2027 ($MILLION)

10. US GRAVES' DISEASE MARKET SIZE, 2020-2027 ($MILLION)

11. CANADA GRAVES' DISEASE MARKET SIZE, 2020-2027 ($MILLION)

12. UK GRAVES' DISEASE MARKET SIZE, 2020-2027 ($MILLION)

13. FRANCE GRAVES' DISEASE MARKET SIZE, 2020-2027 ($MILLION)

14. GERMANY GRAVES' DISEASE MARKET SIZE, 2020-2027 ($MILLION)

15. ITALY GRAVES' DISEASE MARKET SIZE, 2020-2027 ($MILLION)

16. SPAIN GRAVES' DISEASE MARKET SIZE, 2020-2027 ($MILLION)

17. REST OF EUROPE GRAVES' DISEASE MARKET SIZE, 2020-2027 ($MILLION)

18. INDIA GRAVES' DISEASE MARKET SIZE, 2020-2027 ($MILLION)

19. CHINA GRAVES' DISEASE MARKET SIZE, 2020-2027 ($MILLION)

20. JAPAN GRAVES' DISEASE MARKET SIZE, 2020-2027 ($MILLION)

21. REST OF ASIA-PACIFIC GRAVES' DISEASE MARKET SIZE, 2020-2027 ($MILLION)

22. REST OF THE WORLD GRAVES' DISEASE MARKET SIZE, 2020-2027 ($MILLION)